TSE:4568Pharmaceuticals
Daiichi Sankyo Expands Vanflyta Access As Oncology Data Shapes Growth Story
Daiichi Sankyo (TSE:4568) has secured public reimbursement in Quebec, Canada for its targeted acute myeloid leukemia treatment Vanflyta.
The change expands access for certain patients with FLT3-ITD positive acute myeloid leukemia within the province’s public healthcare system.
The company is also preparing to present more than 25 oncology abstracts, including pivotal trial updates, at the 2026 ASCO Annual Meeting.
Daiichi Sankyo, known for its oncology and cardiovascular portfolio, is...